
| Home | Bio | Philosophy | Appointments | Conditions Treated | Fees | Articles | Links |
Menstrual Cycle SupportMonograph prepared by Julie Anne Chinnock, ND and Maureen Williams, ND
Chastetree Berry Extract (Vitex agnus castus) |
| Chastetree Berry Extract (Vitex agnus castus) | 150-450mg twice daily |
| Dong Quai Extract (Angelica sinensis Root) | 125-375mg twice daily |
| Wild Yam Extract (Dioscorea villosa Root) | 125-375mg twice daily |
| Bupleurum Root Extract | 125-375mg twice daily |
| Passionflower Extract (Passiflora incarnata) | 75-225mg twice daily |
| Pyridoxine (HCL) | 25-75mg twice daily |
[i] Blumenthal M, Gruenwald J, Hall T, et al (eds). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA, Integrative Medicine Communications, 1998.
[ii] Brown, DJ, “Vitex agnus-castus clinical monograph”, Quarterly Review of Natural Medicine, Summer, 1994; pp 111-121.
[iii] Hobbs, C. Vitex: The Woman’s Herb, Botanica Press, CA, 1990; pp 2-7.
[iv] Felter, HW, Lloyd, JU. 1983 (Originally published 1898), King’s American Dispensatory, Eclectic Medical Publications, Oregon, p.2056.
[v] Sliutz G, Speiser P, et al: Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res 1993; 25: 253-5.
[vi] Jarry H, Leonhardt S & Wuttke W: Agnus Castus As Dopaminergous Effective Principle In Mastodynon N. Zeitschrift Phytother 1991; 12:77-82.
[vii] Jarry H, Leonhardt S, Gorkow C, et al. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: Direct evidence for dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol Diabetes 1994; 102: 448-454.
[viii] Mayo, J. Premenstrual syndrome: A natural approach to management. Clin Nutr Insights 1997; 5: 1-8.
[ix] Bohnert KJ. The use of Vitex agnus castus for hyperprolactinemia. Quarterly Review of Natural Medicine 1997; 19: 21.
[x] Amann W. Removing an ostipation using Agnolyt. Ther Gegenew 1965; 104 (9): 1263-5.
[xi] Weiss RF. Herbal Medicine. Ab Arcanum, Sweden, 1988.
[xii] Christie, S., Walker, A. (1997) Vitex agnus castus, A review of its traditional
and modern therapeutic use,current use from a survey of practioners. The
European J of Herb Med., 3, 29-45.
[xiii] Berne, M.R., Levy, N.M., Koeppen, M.B., Stanton, A.B. (1998) Physiology,
4th ed, Chapter 52 (The reproductive glands), Pub of Mosby, 965-1014.
[xiv] Kacsoh, B. (2000) Endocrine physiology, Chapter 13 (Reproductive
Endocrinology), pub of Mc Graw Hill, p:448-640.
[xv] Gomaa CS. Flavonoids and iridoids from Vitex agnus castus. Planta Medica 1978; 33: 277.
[xvi] Snow JM. Vitex agnus-castus L. (Verbenaceae). Protocol J Botanic Med 1996; 1(4): 2-7.
[xvii] Loch E, Bohnert KJ, Peters M, et al. The treatment of menstrual disorders with Vitex agnus-castus tincture. Der Frauenarzt 1991; 32: 867-870.
[xviii] Coeugniet E, Elek E, Kuhnnast R. Premenstrual Syndrome (PMS) and its treatments. Arztezeitchr Naturheilverf 1986; 27 (9): 619-22.
[xix] Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract; prospective, randomized, placebo controlled study. BMJ 2001; 322(7279); 134-7.
[xx] Dittmnar F, Bohnnert KJ, Peeters M, et al. Premenstrual syndrome: Treatment with a phytopharmaceutical. Therapiewoche Gynakol 1992; 5: 60-68.
[xxi] Zhu DP. Dong quai. Am J Chin Med 1987;15(3-4):117-25.
[xxii] The World Preservation Society, Inc. Powerful and Unusual Herbs from the Amazon and China. 1993,1995.
[xxiii] Murray, M. The Healing Power of Herbs. Prima Publishing, 1995.
[xxiv] Chang HM, But PP. Pharmacology and applications of Chinese material medica, vol 1. World Scientific, Singapore, 1987; pp 489-505.
[xxv] Tyler V. The Honest Herbal: A Sensible Guide to Herbs and Related Remedies. Philadelphia (PA): George Stickley Company; 1982.
[xxvi] Hardy, ML. Herbs of special interest to women. J Am Pharm Assoc (Wash) 2000 Mar-Apr;40(2):234-42; quiz 327-9.
[xxvii] Foster S, et al. Tyler’s Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies, 3rd Ed. New York: Haworth Herbal Press; 1993.
[xxviii] DerMarderosian A, editor. The Review of Natural Products. St. Louis: Facts and Comparisons; 1999.
[xxix] Goh SY, Koh KC. Gynaecomastia and the herbal tonic “dong quai". Singapore Med J 2001;42:115-6.
[xxx] Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy 1999;19:870-6.
[xxxi] Walker, M. Medicinal Wild Yam. Health Food Business. March 1996.
[xxxii] PDR for Herbal Medicines. 1st Ed. Medical Economics Company. Montvale, NJ, 1998.
[xxxiii] Bruneton, Jean. Pharmacognosy: Phytochemistry Medicinal Plants. Lavoisier Publishing. Paris. 2001. P. 334,
[xxxiv] Bown, D. Encyclopedia of Herbs and Their Uses. New York: DK Publishing, Inc. 1995; 323.
[xxxv] Ellingwood, F. American Materia Medica, Therapeutics and Pharmacognosy. Portland, OR: Eclectic Medical Publications [reprint of 1919 original] 1983.
[xxxvi] Hamel, P.B. and M.U. Chiltoskey. Cherokee Plants and Their UsesA 400 Year History. Sylva, NC: Herald Publishing Company, 1975.
[xxxvii] Bradley, P.R. (ed.). 1992. British Herbal Compendium, Vol. 1. Bournemouth: British Herbal Medicine Association.
[xxxviii] Newall, C.A., L.A. Anderson, J.D. Phillipson. 1996. Herbal Medicines: A Guide for Health-Care Professionals. London: The Pharmaceutical Press.
[xxxix] Bruneton, J. 1995. Pharmacognosy, Phytochemistry, Medicinal Plants. Paris: Lavoisier Publishing.
[xl] ESCOP. 1997. "Passiflorae herba." Monographs on the Medicinal Uses of Plant Drugs. Exeter, U.K.: European Scientific Cooperative on Phytotherapy.
[xli] Wichtl, M. and N.G. Bisset (eds.). 1994. Herbal Drugs and Phytopharmaceuticals. Stuttgart: Medpharm Scientific Publishers.
[xlii] Akhondzadeh S, Naghavi HR, Vazirian M, et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther Oct 2001;26(5):363-7.
[xliii] Brasseur T, Angenot L. The pharmacognosy of the passion flower. J Pharm Belg Jan-Feb 1984;39(1):15-22.
[xliv] Coleta M, Campos MG, Cotrim MD, Proenca da Cunha A. Comparative evaluation of Melissa officinalis L., Tilia europaea L., Passiflora edulis Sims. and Hypericum perforatum L. in the elevated plus maze anxiety test. Pharmacopsychiatry Jul 2001;34 Suppl 1:S20-1.
[xlv] Dhawan K, Kumar S, Sharma A. Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. J Ethnopharmacol Dec 2001;78(2-3):165-70.
[xlvi] Dhawan K, Kumar S, Sharma A. Anxiolytic activity of aerial and underground parts of Passiflora incarnata. Fitoterapia. Dec 2001;72(8):922-6.
[xlvii] Gerhard U, Hobi V, Kocher R, Konig C. Acute sedative effect of a herbal relaxation tablet as compared to that of bromazepam. Schweiz Rundsch Med Prax Dec 1991 27;80(52):1481-6.
[xlviii] Krenn L. [Passion Flower (Passiflora incarnata L.)--a reliable herbal sedative] Wien Med Wochenschr 2002;152(15-16):404-6.
[xlix] Motoo Y, Sawabu N. Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer Lett 1994;86:915.
[l] Yamamoto M, Kumagai A, Yamamura Y. Structure and actions of saikosaponins isolated from Bupleurum falcatum L. I. Anti-inflammatory action of saikosaponins. Arzneim Forsch 1975;25:10213.
[li] Utrilla MP, Zarzuelo A, Risco S, et al. Isolation of a saikosaponin responsible for the antiinflammatory activity of Bupleurum gibralticum Lam root extract. Phytother Res 1991;5:435.
[lii] Martin S, Padilla E, Ocete M A, et al. Anti-inflammatory activities of the essential oils of Bupleurum fruticescens. Planta Medica 1993;59:533-6.
[liii] Lorente I, Ocete MA, Zarzuelo A, et al. Bioactivity of the essential oil of Bupleurum fruticosum. J Nat Prod 1989;52:267-72.
[liv] Hirayama C, Okumura M, Tanikawa K, et al. A multicenter randomized controlled clinical trial of sho-saiko-to in chronic active hepatitis. Gastroent Jap 1989;24:7159.
[lv] Fujiwara K, Ohta Y, Ogata I, et al. Treatment trial of traditional Oriental medicine in chronic viral hepatitis. In: Ohta Y (ed). New Trends in Peptic Ulcer and Chronic Hepatitis: Part II. Chronic Hepatitis. Tokyo: Excerpta Medica 1987, 1416.
[lvi] Tajiri H, Kozaiwa K, Osaki Y, et al. The study of the effect of sho-saiko-to on HBeAg clearance in children with chronic HBV infection and with abnormal liver function tests. Acta Paediatr Jpn 1991;94:18115.
[lvii] Gibo Y, Nakamura Y, Takahashi N, et al. Clinical study of sho-saiko-to therapy for Japanese patients with chronic hepatitis C (CH-C). Prog Med 1994;14:2179.
[lviii] Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with sho-saiko-to (TJ-9). Cancer 1995;76:7439.
[lix] Yamamoto S, Oka H, Kanno T, et al. Controlled prospective trial to evaluate Shosaiko-to in preventing hepatocellular carcinoma in patients with cirrhosis of the liver. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 1989;16:151924. [in Japanese]
[lx] Nakagawa A, Yamaguchi I, Takao T, Amano H. Five cases of drug-induced pneumonitis due to sho-saiko-to or interferon alpha or both. Nippon Kyobu Shikkan Gakkai Zasshi 1995;33:13616. [in Japanese]
[lxi] Ishizaki T, Sasaki F, Ameshima S, et al. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 1996;9:26916.
[lxii] Sugiyama H, Nagai M, Kotajima F, et al. A case of interstitial pneumonia with chronic hepatitis C following interferon-alpha and sho-saiko-to therapy. Arerugi 1995;44:7114. [in Japanese]
[lxiii] Sato A, Toyoshima M, Kondo A, et al. Pneumonitis induced by the herbal medicine Sho-saiko-to in Japan. Nippon Kyobu Shikkan Gakkai Zasshi 1997;35:3915. [in Japanese]
[lxiv] Miyazaki E, Ando M, Ih K, et al. Pulmonary edema associated with the Chinese medicine shosaikoto. Nihon Kokyuki Gakkai Zasshi 1998;36:77680. [in Japanese]
[lxv] Diegoli MS, da Fonseca AM, Diegoli CA, Pinotti JA. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet 1998;62:63-7.
[lxvi] Brush MG, Bennett T, Hansen K. Pyridoxine in the treatment of premenstrual syndrome: a retrospective survey in 630 patients. Br J Clin Pract 1988;42:448-52.
[lxvii] Williams MJ, Harris RI, Dean BC. Controlled trial of pyridoxine in the premenstrual syndrome. J Int Med Res 1985;13:174-9.
[lxviii] Hagen I, Nesheim BI, Tuntland T. No effect of vitamin B-6 against premenstrual tension. A controlled clinical study. Acta Obstet Gynecol Scand 1985;64:667-70.
[lxix] Doll H, Brown S, Thurston A, Vessey M. Pyridoxine (vitamin B6) and the premenstrual syndrome: a randomized crossover trial. J R Coll Gen Pract 1989;39:364-8.
[lxx] Sharma P, Kulshreshtha S, Singh GM, Bhagoliwal A. Role of bromocriptine and pyridoxine in premenstrual tension syndrome. Indian J Physiol Pharmacol 2007;51:368-74.
[lxxi] De Souza MC, Walker AF, Robinson PA, Bolland K. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med 2000;9:131-9.